[Taiwan Semiconductor Manufacturing Company Ltd. By Lora Ho Senior Vice President & Chief Financial Officer TSMC Reports First Quarter EPS of NT$3.46 Hsinchu, Taiwan, R.O.C., April 19, 2018 Year-over-year, first quarter revenue increased 6.1% while net income and diluted EPS both increased 2.5%. Co]
[Number 99.1 Annual Report 2017. SINOPEC SHANGHAI PETROCHEMICAL COMPANY LIMITED Wu Haijun President Important Message 2 Definitions 4 Company Profile 5 Financial Highlights 6 Principal Products 11 Change in Share Capital of Ordinary Shares and Shareholders 13 Directors, Supervisors, Senior Management]
[Taiwan Semiconductor Manufacturing Company Ltd. By Lora Ho Senior Vice President & Chief Financial Officer TSMC Reports First Quarter EPS of NT$3.46 Hsinchu, Taiwan, R.O.C., April 19, 2018 Year-over-year, first quarter revenue increased 6.1% while net income and diluted EPS both increased 2.5%. Co]
[Number 99.1 Annual Report 2017. SINOPEC SHANGHAI PETROCHEMICAL COMPANY LIMITED Wu Haijun President Important Message 2 Definitions 4 Company Profile 5 Financial Highlights 6 Principal Products 11 Change in Share Capital of Ordinary Shares and Shareholders 13 Directors, Supervisors, Senior Management]
[Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [x] Emerging growth company [ ] † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. U.S.]
[Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd. - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary – - Reaffirms Commitment to Take All Appropriate Actions to Protect Compan]
[Sinovac Announces Preliminary Results of Phase III Trial on sIPV BEIJING, April 19, 2018 -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactiva]
[Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [x] Emerging growth company [ ] † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. U.S.]
[Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd. - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary – - Reaffirms Commitment to Take All Appropriate Actions to Protect Compan]
[Title of each class Name of each exchange on which registered American Depositary Shares* Class H Ordinary Shares** _______________________ * Evidenced by American Depositary Receipts. Each American Depositary Share represents 25 H Shares. ** Indicate the number of outstanding shares of each of the ]
